NEW YORK (GenomeWeb News) – Invitrogen and Applied Biosystems announced separately today that their respective shareholders have voted in favor of the firms’ $6.7 billion merger.
 
Both firms said that around 98 percent of their respective shares were cast in favor of the deal, which is expected to close next month. The transaction already has cleared US antitrust hurdles but still requires clearance from European Union regulators.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Sometimes genetic tests give inconclusive results and provide little reassurance to patients, the Associated Press reports.

Vox wonders whether gene-editing crops will be viewed similarly as genetically modified organisms of if people will give them a try.

In Science this week: research regulation and reporting requirement reform, and more.

NPR reports that government and private insurers are being slow to cover recently approved CAR-T cell therapies.